SymBio Announces Completion of Patient Enrollment of TREAKISYM® (SyB L ... Marketwire (press release) This randomized trial is evaluating the combination of TREAKISYM® and rituximab versus R-CHOP 2. SymBio initiated this multicenter open-label Phase II trial as a line extension study for TREAKISYM® in November, 2011, in collaboration with Eisai. |
